Serial MRI and CSF biomarkers in normal aging, MCI, and AD

Objective: To compare the annual change in MRI and CSF biomarkers in cognitively normal (CN), amnestic mild cognitive impairment (aMCI), and Alzheimer disease (AD). Comparisons were based on intergroup discrimination, correlation with concurrent cognitive/functional changes, relationships to APOE genotype, and sample sizes for clinical trials. Methods: We used data from the Alzheimer's Disease Neuroimaging Initiative study consisting of CN, aMCI, and AD cohorts with both baseline and 12-month follow-up CSF and MRI. The annual change in CSF (total-tau [t-tau], Aβ1-42) and MRI (change in ventricular volume) was obtained in 312 subjects (92 CN, 149 aMCI, 71 AD). Results: There was no significant average annual change in either CSF biomarker in any clinical group except t-tau in CN; moreover, the annual change did not differ by clinical group in pairwise comparisons. In contrast, annual increase in ventricular volume increased in the following order, AD > aMCI > CN, and differences were significant between all clinical groups in pairwise comparisons. Ventricular volume increase correlated with concurrent worsening on cognitive/functional indices in aMCI and AD whereas evidence of a similar correlation with change in CSF measures was unclear. The annual changes in MRI differed by APOE ε4 status overall and among aMCI while annual changes in CSF biomarkers did not. Estimated sample sizes for clinical trials are notably less for MRI than the CSF or clinical measures. Conclusions: Unlike the CSF biomarkers evaluated, changes in serial structural MRI are correlated with concurrent change on general cognitive and functional indices in impaired subjects, track with clinical disease stage, and are influenced by APOE genotype.

[1]  Hilkka Soininen,et al.  J-ADNI and selection of cognition measures , 2010, Alzheimer's & Dementia.

[2]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[3]  M. Bobinski,et al.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease , 1999, Neuroscience.

[4]  Norbert Schuff,et al.  3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry , 2008, NeuroImage.

[5]  J. Schneider,et al.  Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease , 2002, Annals of neurology.

[6]  M. Weiner,et al.  Correlates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia , 2005, Annals of neurology.

[7]  Nick C Fox,et al.  Combining short interval MRI in Alzheimer’s disease , 2006, Journal of Neurology.

[8]  S. Leurgans,et al.  MRI predictors of risk of incident Alzheimer disease , 2005, Neurology.

[9]  Nick C. Fox,et al.  The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI , 1997, IEEE Transactions on Medical Imaging.

[10]  W. Markesbery,et al.  Hippocampal volume as an index of Alzheimer neuropathology: Findings from the Nun Study , 2002, Neurology.

[11]  R. Bartha,et al.  Ventricular enlargement as a possible measure of Alzheimer's disease progression validated using the Alzheimer's disease neuroimaging initiative database. , 2008, Brain : a journal of neurology.

[12]  K. Blennow,et al.  Increasing CSF phospho-tau levels during cognitive decline and progression to dementia , 2008, Neurobiology of Aging.

[13]  Nick C Fox,et al.  Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Nick C Fox,et al.  Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations , 2010, European Radiology.

[15]  C. Jack,et al.  Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia , 2002, Neurology.

[16]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[17]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[18]  Michael Weiner,et al.  Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease , 2009, Annals of neurology.

[19]  C. Jack,et al.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD , 2003, Neurology.

[20]  Cindee M. Madison,et al.  Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.

[21]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[22]  Nick C Fox,et al.  Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.

[23]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[24]  C. Jack,et al.  Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease , 2009, Brain : a journal of neurology.

[25]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[26]  Nick C Fox,et al.  Imaging cerebral atrophy: normal ageing to Alzheimer's disease , 2004, The Lancet.

[27]  C. Jack,et al.  MRI and CSF biomarkers in normal, MCI, and AD subjects , 2009, Neurology.

[28]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[29]  T. Lehtimäki,et al.  Longitudinal stability of CSF tau levels in Alzheimer patients , 1999, Biological Psychiatry.

[30]  H. Soininen,et al.  Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. , 2009, Archives of neurology.

[31]  Nick C Fox,et al.  Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment , 2007, Neurology.

[32]  H. Wiśniewski,et al.  In Vivo Structural Studies of the Hippocampus in Normal Aging and in Incipient Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[33]  Gina N. LaRossa,et al.  Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.

[34]  Kaj Blennow,et al.  Cerebrospinal fluid biomarkers for disease stage and intensity in cognitively impaired patients , 2003, Neuroscience Letters.

[35]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[36]  H. Engler,et al.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.

[37]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[38]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[39]  A. Fagan,et al.  Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly , 2009, Annals of neurology.

[40]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.